We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 17 mei 2018

The Lancet: [News] Reduced-dose dasatinib in chronic-phase CML

[News] Reduced-dose dasatinib in chronic-phase CML
Dasatinib, a tyrosine kinase inhibitor of BCR-ABL1 and Src family kinases, is well tolerated and shows encouraging efficacy at a reduced dose in the front-line treatment of patients with chronic-phase chronic myeloid leukaemia (CML), new research suggests.
Read more

[News] Chemoradiotherapy for pancreatic adenocarcinoma
Treatment of patients with borderline-resectable pancreatic ductal adenocarcinoma with preoperative FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) and individualised chemoradiotherapy leads to encouraging resectability and survival outcomes, according to a recent study.
Read more

[Articles] Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Immune checkpoint inhibitors can improve overall survival for patients with advanced cancers such as melanoma and non-small-cell lung cancer, but the magnitude of benefit is sex-dependent. Future research should guarantee greater inclusion of women in trials and focus on improving the effectiveness of immunotherapies in women, perhaps exploring different immunotherapeutic approaches in men and women.
Read more

[Comment] Does a patient's sex predict the efficacy of cancer immunotherapy?
Cancer immunotherapy undoubtedly represents one of the most important advances in cancer treatment in the past decade.1,2 Among cancer immunotherapies, immune checkpoint inhibitors (including CTLA-4, PD-1, and PD-L1 inhibitors) have attracted the major share of attention of both physicians and patients. Several randomised trials have clearly proven the efficacy of these drugs in the management of several difficult-to-treat malignancies, including malignant melanoma, non-small-cell lung cancer, bladder cancer, and head and neck cancer, among many others.
Read more

[Articles] Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial
The risk-adapted approach did not improve event-free survival in young children with medulloblastoma. However, the methylation subgroup analyses showed that the SHH subgroup had improved progression-free survival compared with the group 3 subgroup. Moreover, within the SHH subgroup, the iSHH-II subtype had improved progression-free survival in the absence of radiation, intraventricular chemotherapy, or high-dose chemotherapy compared with the iSHH-I subtype. These findings support the development of a molecularly driven, risk-adapted, treatment approach in future trials in young children with medulloblastoma.
Read more